Deciphera Pharmaceuticals, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 20 rows in 2023. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2023-09-15: Reporting owner Dhanak Dashyant; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2023-06-21: Reporting owner Martin John Richard; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2023-06-21: Reporting owner Benz Edward J. JR; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2023-06-21: Reporting owner Bristol James Arthur; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2023-09-15 | Dhanak Dashyant Officer (EVP & Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +65,900 65,900 owned after | $13.42 exercise price | 2023-09-19 | |
| 2023-06-21 | Martin John Richard Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $14.91 exercise price | 2023-06-23 | |
| 2023-06-21 | Benz Edward J. JR Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $14.91 exercise price | 2023-06-23 | |
| 2023-06-21 | Bristol James Arthur Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $14.91 exercise price | 2023-06-23 | |
| 2023-06-21 | Friedman Franklin Stuart Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $14.91 exercise price | 2023-06-23 | |
| 2023-06-21 | Walsh Dennis Leo Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $14.91 exercise price | 2023-06-23 | |
| 2023-06-21 | Kelley Susan L. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $14.91 exercise price | 2023-06-23 | |
| 2023-06-21 | Squarer Ron Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $14.91 exercise price | 2023-06-23 | |
| 2023-06-21 | Allen Patricia L Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $14.91 exercise price | 2023-06-23 | |
| 2023-02-15 | Pitman Jama Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +44,600 44,600 owned after | $15.48 exercise price | 2023-02-17 | |
| 2023-02-15 | Martin Daniel C. Officer (Chief Commercial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +44,600 44,600 owned after | $15.48 exercise price | 2023-02-17 | |
| 2023-02-15 | Kelly Thomas Patrick Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +65,900 65,900 owned after | $15.48 exercise price | 2023-02-17 | |
| 2023-02-15 | Sherman Matthew L Officer (EVP & Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +65,900 65,900 owned after | $15.48 exercise price | 2023-02-17 | |
| 2023-02-15 | Flynn Daniel Lee Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +65,900 65,900 owned after | $15.48 exercise price | 2023-02-17 | |
| 2023-02-15 | Hoerter Steven L. Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +250,000 250,000 owned after | $15.48 exercise price | 2023-02-16 | |
| 2023-01-17 | Friedman Franklin Stuart Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,269 3,269 owned after | $15.30 | 2023-01-19 | |
| 2023-01-17 | Allen Patricia L Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,269 3,269 owned after | $15.30 | 2023-01-19 | |
| 2023-01-17 | Walsh Dennis Leo Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,269 3,269 owned after | $15.30 | 2023-01-19 | |
| 2023-01-17 | Squarer Ron Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,269 3,269 owned after | $15.30 | 2023-01-19 | |
| 2023-01-17 | Kelley Susan L. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,269 3,269 owned after | $15.30 | 2023-01-19 |